Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | USP1 | O94782 | 1/20 | 0.53 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3109840 | 0.88 | APP (0.65) | APPPOLBEGFRNR2F2SLC2A1 | |
| SCHEMBL3118629 | 0.85 | APP (0.68) | APPPOLBEGFRNR2F2SLC2A1 | |
| SCHEMBL3118894 | 0.85 | APP (0.74) | APPPOLBEGFRNR2F2SLC2A1 | |
| SCHEMBL3124803 | 0.85 | APP (0.61) | APPPOLBEGFRNR2F2SLC2A1 | |
| SCHEMBL3119546 | 0.85 | APP (0.61) | APPPOLBEGFRNR2F2SLC2A1 | |
| SCHEMBL3113216 | 0.84 | APP (0.60) | APPPOLBEGFRNR2F2SLC2A1 | |
| SCHEMBL3119175 | 0.81 | APP (0.68) | APPPOLBEGFRNR2F2SLC2A1 | |
| SCHEMBL4737097 | 0.80 | APP (0.55) | APPPOLBEGFRNR2F2SLC2A1 | |
| SCHEMBL3108497 | 0.80 | APP (0.67) | APPPOLBEGFRNR2F2SLC2A1 | |
| SCHEMBL3115246 | 0.79 | APP (0.70) | APPPOLBEGFRNR2F2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | claimed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | APP 2989/4885POLB 1857/4885EGFR 3147/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | APP 3261/4885POLB 1789/4885EGFR 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.